Scholarlink

<p>Pharmaceutical stability studies ensure medications meet standards, but real-world use can differ from controlled trials. Post-approval, medicines may change, necessitating careful consideration during their transition to market. Nanomedicine emphasizes stability, with testing for environmental factors crucial to ensure drug safety, efficacy, and quality, especially in cancer treatment applications. Maintaining physicochemical stability is vital for successful commercialization. In our project, we investigated the thermal behavior and structural changes of Gold Nanoparticles (GNPs, ~ 20&#xa0;nm), Iron Oxide Nanoparticles (MIONPs, ~ 16&#xa0;nm), Doxorubicin, Cisplatin, and their conjugates. We employed Thermogravimetric (TG) analysis and Differential Scanning Calorimetry (DSC) to measure properties such as thermal pattern and mass as a function of temperature. As shown by TG analysis, thermal degradation of Doxorubicin and Cisplatin commenced at 190&#xa0;°C and 250&#xa0;°C, respectively. In the DSC analysis, endothermic peaks were observed at 220&#xa0;°C and 318&#xa0;°C, corresponding to DOX and Cis-Pt molecular structure degradation. Notably, the endothermic peak for DOX@GNPs appeared at a temperature 30&#xa0;°C higher than that of the pure form, indicating enhanced conjugate stability. Conversely, the decomposition temperature for DOX@MIONPs decreased by approximately 10% compared to pure DOX, suggesting reduced conjugate stability. A similar decrease in stability was observed for Cis-Pt@GNPs and Cis-Pt@MIONPs, by 1% and 25%, respectively. In general, the results indicate that the conjugation of both drugs with GNPs provides more stable conditions than with MIONPs. This study marks the beginning of a significant trend in evaluating the stability of platforms designed for targeted drug delivery, ensuring that drugs’ lifetimes are not compromised under conjugation conditions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Thermal Resilience of Drug-Nanoparticle Hybrids: Insights for Targeted Delivery Systems

  • 期刊论文

  • 发表日期：

    2025年1月22日

查看全文
  • Alireza Soroush,
  • Hamed Zandavar,
  • Seied Mahdi Pourmortazavi,
  • Somayeh Mirsadeghi

摘要

Pharmaceutical stability studies ensure medications meet standards, but real-world use can differ from controlled trials. Post-approval, medicines may change, necessitating careful consideration during their transition to market. Nanomedicine emphasizes stability, with testing for environmental factors crucial to ensure drug safety, efficacy, and quality, especially in cancer treatment applications. Maintaining physicochemical stability is vital for successful commercialization. In our project, we investigated the thermal behavior and structural changes of Gold Nanoparticles (GNPs, ~ 20 nm), Iron Oxide Nanoparticles (MIONPs, ~ 16 nm), Doxorubicin, Cisplatin, and their conjugates. We employed Thermogravimetric (TG) analysis and Differential Scanning Calorimetry (DSC) to measure properties such as thermal pattern and mass as a function of temperature. As shown by TG analysis, thermal degradation of Doxorubicin and Cisplatin commenced at 190 °C and 250 °C, respectively. In the DSC analysis, endothermic peaks were observed at 220 °C and 318 °C, corresponding to DOX and Cis-Pt molecular structure degradation. Notably, the endothermic peak for DOX@GNPs appeared at a temperature 30 °C higher than that of the pure form, indicating enhanced conjugate stability. Conversely, the decomposition temperature for DOX@MIONPs decreased by approximately 10% compared to pure DOX, suggesting reduced conjugate stability. A similar decrease in stability was observed for Cis-Pt@GNPs and Cis-Pt@MIONPs, by 1% and 25%, respectively. In general, the results indicate that the conjugation of both drugs with GNPs provides more stable conditions than with MIONPs. This study marks the beginning of a significant trend in evaluating the stability of platforms designed for targeted drug delivery, ensuring that drugs’ lifetimes are not compromised under conjugation conditions.